OSE Immunotherapeutics (XPAR:OSE) FCF Margin %: -1,148.77% (As of Dec. 2025)

What is OSE Immunotherapeutics FCF Margin %?

OSE Immunotherapeutics XPAR:OSE -4.98% 53 FCF Margin % is -1,148.77% as of Dec. 2025. GuruFocus rates XPAR:OSE with a GF Score™ of 53/100 and a GF Value™ of €1.49 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, OSE Immunotherapeutics ranks worse than 80.92% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OSE Immunotherapeutics's Free Cash Flow for the six months ended in Dec. 2025 was €-14.89 Mil. OSE Immunotherapeutics's Revenue for the six months ended in Dec. 2025 was €1.30 Mil. Therefore, OSE Immunotherapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was -1,148.77%.

As of today, OSE Immunotherapeutics's current FCF Yield % is -47.64%.

The historical rank and industry rank for OSE Immunotherapeutics's FCF Margin % or its related term are showing as below:

XPAR:OSE' s FCF Margin % Range Over the Past 10 Years
Min: -1303.32 Med: -70.36 Max: 170.76
Current: -1303.32

During the past 13 years, the highest FCF Margin % of OSE Immunotherapeutics was 170.76%. The lowest was -1303.32%. And the median was -70.36%.

XPAR:OSE's FCF Margin % is ranked worse than
80.92% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs XPAR:OSE: -1303.32

OSE Immunotherapeutics FCF Margin % Related Terms

OSE Immunotherapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics FCF Margin % Chart

OSE Immunotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-39.50

-101.22

-888.19

69.21

-1,303.32

OSE Immunotherapeutics Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
FCF Margin %	Get a 7-Day Free Trial															-924.97	96.14	-2,167.87	-1,454.72	-1,148.77

XPAR:OSE vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, OSE Immunotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OSE Immunotherapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's FCF Margin % falls into.

Save Embed

53GF Score

OSE Immunotherapeutics SA XPAR:OSE

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

OSE Immunotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OSE Immunotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-34.134	/	2.619
	=	-1,303.32 %

OSE Immunotherapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-14.888	/	1.296
	=	-1,148.77 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -1,148.77% mean?

OSE Immunotherapeutics (XPAR:OSE) has a FCF Margin % of -1,148.77% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OSE Immunotherapeutics and its competitors. According to the industry distribution chart, OSE Immunotherapeutics ranks #776 out of 959 companies in the Biotechnology industry, placing it in the top 80.9%.

Is OSE Immunotherapeutics' FCF Margin % too high?

OSE Immunotherapeutics' current FCF Margin % is -1,148.77%. Based on the distribution chart, OSE Immunotherapeutics ranks #776 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OSE Immunotherapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does OSE Immunotherapeutics' FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #776 out of 959 companies for FCF Margin %. This places OSE Immunotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current FCF Margin % is -1,148.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is OSE Immunotherapeutics stock overvalued right now?

Based on GuruFocus' analysis, OSE Immunotherapeutics (XPAR:OSE) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.49, compared to a current price of €3.05 — trading 104.7% above its estimated fair value. The current FCF Margin % is -1,148.77%. OSE Immunotherapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For OSE Immunotherapeutics (XPAR:OSE), the current FCF Margin % is -1,148.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (XPAR:OSE) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of €3.05 is trading 104.7% above its estimated GF Value™ of €1.49. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:OSE:

FCF Margin %: -1,148.77%
GF Value™: €1.49 vs. price of €3.05 (104.7% above fair value)
GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the XPAR:OSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies XPAR:ABNX XPAR:ALVIO XPAR:ADOC XPAR:ALGAE XPAR:ALTHX XPAR:MAAT XPAR:IPH XPAR:ALCOX XPAR:MLINA XPAR:ALGEN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ORPOF:USA 0RAD:UK 6OP:Germany

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200

Website http://www.ose-immuno.com

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

53GF Score

Get the complete analysis for XPAR:OSE

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.05

Price

€1.49

GF Value

View XPAR:OSE Analysis

See FCF Margin % data for all stocks →